SkinBioTherapeutics ( (GB:SBTX) ) just unveiled an update.
SkinBioTherapeutics plc announced the exercise of warrants by Macquarie for 250,000 ordinary shares at £0.2043 per share, increasing the company’s total issued shares to 231,975,383. This development reflects the company’s ongoing efforts to strengthen its financial position and expand its market presence, potentially impacting shareholder interests and enhancing its industry positioning.
More about SkinBioTherapeutics
SkinBioTherapeutics is a life science company focused on skin health, utilizing its proprietary platform technology, SkinBiotix®, developed by the University of Manchester’s dermatology team. The company targets the skin healthcare market through five pillars, with a focus on cosmetic skincare and food supplements, such as AxisBiotix-Ps™, to address psoriasis symptoms. It collaborates with Croda plc and pursues acquisitions to expand its distribution and manufacturing capabilities.
YTD Price Performance: 27.03%
Average Trading Volume: 699,418
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £56.19M
For an in-depth examination of SBTX stock, go to TipRanks’ Stock Analysis page.